ACBI-4
Based on 1 Customer Validation
ACBI-4 is a selective GTP-loaded active state of KRAS (KRAS(on)) PROTAC degrader, with Kd values of 141 nM against KRASG12R. ACBI-4 forms a stable ternary complex with VHL, triggering ubiquitination and KRAS degradation via the ubiquitin-proteasome system. ACBI-4 induces antiproliferative effects in KRAS mutant-driven cancer cells. ACBI-4 can be used for the research of KRAS mutant-driven cancer.
(Pink: KRas G12R ligand (HY-162960); Blue: VHL ligand (HY-176917); Black: linker).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.01%
- CAS 番号: 3097985-19-5
- 分子式: C50H63N15O4S
- 分子量:970.20
-
保管条件:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
PROTACs アイソフォーム固有の製品をすべて表示
More
生物活性
|
KRas G12R 141 nM (Kd) |
ACBI-4 (0.01-10 μM) potently degrades endogenous KRASG12R in Cal-62 cells with a DC50 of 162 nM and 93% maximal degradation at 18 h, acting via a PROTAC-dependent mechanism involving VHL recruitment and proteasomal degradation[1].
ACBI-4 (0.1 nM-10 μM; 6 day) exerts a dose-dependent antiproliferative effect in KRASG12R-driven Cal-62 cells, with no activity in KRAS-independent A375 cells, demonstrating on-target efficacy[1].
ACBI-4 (0.02-1000 nM; 18 h) degrades all tested oncogenic KRAS mutants in transduced GP5d cells, with notably enhanced degradation of KRASG12R, KRASQ61K, KRASQ61L, and KRASQ61R compared to ACBI3 (HY-157228)[1].
ACBI-4 (0.01-10 μM; 18 h) degrades endogenous KRASG12R, KRASQ61K, KRASQ61L, and KRASG12D in their respective cancer cell lines in a dose-dependent manner[1].
ACBI-4 (0.1-10 μM) degrades HiBiT-tagged KRASG12R in Cal-62 cells at a faster rate than compound 1, with a maximum rate of ~0.3 min−1 at concentrations ≥1 μM[1].
ACBI-4 (1 μM; 6 h) selectively degrades KRAS in Cal-62 cells, with minimal degradation of closely related NRAS and HRAS at therapeutic-relevant concentrations, and modulates levels of MAPK pathway-related proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cal-62 (KRASG12R) cancer cells, KRAS-independent A375 cells
-
Concentration:0.1 nM; 1 nM; 10 nM; 100 nM; 1 μM; 10 μM
-
Incubation Time:6 day
-
Result:Induced a dose-dependent antiproliferative effect in Cal-62 cells.
Showed no antiproliferative activity in KRAS-independent A375 cells, confirming on-target activity.
-
Cell Line:retrovirally transduced GP5d cells (multiple KRAS mutants)
-
Concentration:0.02 nM; 0.15 nM; 0.46 nM; 1.4 nM; 4 nM; 12 nM; 37 nM; 111 nM; 333 nM; 1000 nM
-
Incubation Time:18 h
-
Result:Degraded all tested oncogenic KRAS mutants, including KRASG12R, KRASQ61K, KRASQ61L, KRASQ61R, KRASG12D, KRASG12V, KRASG13D, KRASG13V, KRASQ61E, KRASA146P, KRASA146T, and KRASA146V.
Showed significantly improved degradation of KRASG12R, KRASQ61K, KRASQ61L, and KRASQ61R compared to ACBI3, with only KRASA146P showing similar degradation levels to ACBI3.
-
Cell Line:Calu-6 (KRASQ61K), SW948 (KRASQ61L), KP-2 (KRASG12R), GP5d (KRASG12D)
-
Concentration:0.01 μM; 0.03 μM; 0.1 μM; 0.3 μM; 1 μM; 10 μM
-
Incubation Time:18 h
-
Result:Induced dose-dependent degradation of endogenous KRASQ61K in Calu-6 cells.
Induced dose-dependent degradation of endogenous KRASQ61L in SW948 cells, requiring higher concentrations for maximal effect.
Induced dose-dependent degradation of endogenous KRASG12R in KP-2 cells.
Induced dose-dependent degradation of endogenous KRASG12D in GP5d cells.
化学情報
-
CAS 番号 3097985-19-5
-
性状 Solid
-
分子量 970.20
-
分子式 C50H63N15O4S
-
Color White to off-white
-
SMILES
CC([C@H](N1N=NC2=C1CC[C@H](CCCN3C[C@@H](N(CCC3)C4=NC(C5=NOC([C@@]6(C7=C(CCC6)SC(N)=C7C#N)C)=N5)=CC=N4)C)C2)C(N8C[C@@H](C[C@H]8C(NCC9=CC=C%10C(N(N=C%10)C)=C9)=O)O)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
DMSO : 50 mg/mL (51.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0307 mL | 5.1536 mL | 10.3072 mL | 25.7679 mL |
| 5 mM | 0.2061 mL | 1.0307 mL | 2.0614 mL | 5.1536 mL | |
| 10 mM | 0.1031 mL | 0.5154 mL | 1.0307 mL | 2.5768 mL | |
| 15 mM | 0.0687 mL | 0.3436 mL | 0.6871 mL | 1.7179 mL | |
| 20 mM | 0.0515 mL | 0.2577 mL | 0.5154 mL | 1.2884 mL | |
| 25 mM | 0.0412 mL | 0.2061 mL | 0.4123 mL | 1.0307 mL | |
| 30 mM | 0.0344 mL | 0.1718 mL | 0.3436 mL | 0.8589 mL | |
| 40 mM | 0.0258 mL | 0.1288 mL | 0.2577 mL | 0.6442 mL | |
| 50 mM | 0.0206 mL | 0.1031 mL | 0.2061 mL | 0.5154 mL |
ACBI-4 関連分類
HY-176792 関連分類
Powered by Bioz